Wikisage, the free encyclopedia of the second generation, is digital heritage

Eslicarbazepine: Difference between revisions

From Wikisage
Jump to navigation Jump to search
Line 10: Line 10:
==Pharmacology==
==Pharmacology==


[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4448990/ Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action]
*[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4448990/ Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action]
 
*[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4330027/ Clinical utility of eslicarbazepine: current evidence]
===Mild inducers===
===Mild inducers===
After de Leon the following AED groups as mild inducers:
After de Leon the following AED groups as mild inducers:

Revision as of 04:12, 20 September 2015

S-licarbazepine is an AED. Adjunctive eslicarbazepine led to seizure reduction in patients with severe myoclonic epilepsy of infancy[1][2]

Pharmacy and chemistry

Eslicarbamazepine acetate is an once-daily antiepileptic that was approved in 2009 by the EMA (Zerebix TM) and recently by the American FDA[3] Eslicarbamazepine is the prodrug of S-licarbazepine, both oxcarbazapine and eslicarbazepine metabolize same, different to carbazepine; the latter metabolizes to CBZ 10,11-epoxide (Hainzl et al, 2001)[4]

Pharmacology

Mild inducers

After de Leon the following AED groups as mild inducers:

  • clobazam
  • eslicarbazepine
  • rufinamide
  • felbamate
  • lamotrigine
  • oxcarbazepine
  • topiramate
  • vigabatrin
  • VPA

[5]

Cutaneous adverse effects

Cutaneous adverse drug reaction type erythema multiforme major induced by eslicarbazepine

ATC code N03

eslicarbazapine
[6]

References